Search research articles
Contact Us
Filters
Showing results (1-10 of 46) with videos related to
Page
of 5
Sort By:
British Journal of Clinical Pharmacology
|
June 20, 2025
Letter to the editor of the Brit J Clin Pharmacol on Heuberger et al. 2025 https://doi.org/10.1002/bcp.70090
Markus Hinder, Vikram P Sinha
British Journal of Clinical Pharmacology
|
May 10, 2026
Letter to the Editor of the British Journal of Clinical Pharmacology Re: van Iersel et al. (2026)-Why do healthy volunteers participate in clinical trials? doi: https://doi.org/10.1002/bcp.70499
Kasra Shakeri-Nejad, Markus Hinder
Journal of Translational Medicine
|
April 28, 2016
Changing R&D models in research-based pharmaceutical companies
Alexander Schuhmacher, Oliver Gassmann, Markus Hinder
Drug Discovery Today
|
July 20, 2019
The Art of Virtualizing Pharma R&D
Alexander Schuhmacher, Oliver Gassmann, Michael Kuss, et al.
Journal of Translational Medicine
|
May 10, 2018
Open innovation and external sources of innovation. An opportunity to fuel the R&D pipeline and enhance decision making?
Alexander Schuhmacher, Oliver Gassmann, Nigel McCracken, et al.
Drug Discovery Today
|
August 3, 2024
Comparative analysis of FDA approvals by top 20 pharma companies (2014-2023)
Alexander Schuhmacher, Oliver Gassmann, Markus Hinder, et al.
Drug Discovery Today
|
September 20, 2025
The Role of Data Monitoring Committees in drug research
Markus Hinder, Nandhini Madesh, Dominik Hartl, et al.
Clinical Pharmacology and Therapeutics
|
January 10, 2018
Developing Drugs for Heart Failure With Reduced Ejection Fraction: What Have We Learned From Clinical Trials?
Markus Hinder, B Alexander Yi, Thomas H Langenickel
Drug Discovery Today
|
August 4, 2020
The present and future of project management in pharmaceutical R&D
Alexander Schuhmacher, Oliver Gassmann, Markus Hinder, et al.
Drug Discovery Today
|
June 1, 2022
Open innovation: A paradigm shift in pharma R&D?
Alexander Schuhmacher, Oliver Gassmann, Doria Bieniok, et al.
Page
of 5
Search research articles
Search
Showing results (1-10 of 46) with videos related to
Sort By:
Page
of 5
British Journal of Clinical Pharmacology
|
June 20, 2025
Letter to the editor of the Brit J Clin Pharmacol on Heuberger et al. 2025 https://doi.org/10.1002/bcp.70090
Markus Hinder, Vikram P Sinha
British Journal of Clinical Pharmacology
|
May 10, 2026
Letter to the Editor of the British Journal of Clinical Pharmacology Re: van Iersel et al. (2026)-Why do healthy volunteers participate in clinical trials? doi: https://doi.org/10.1002/bcp.70499
Kasra Shakeri-Nejad, Markus Hinder
Journal of Translational Medicine
|
April 28, 2016
Changing R&D models in research-based pharmaceutical companies
Alexander Schuhmacher, Oliver Gassmann, Markus Hinder
Drug Discovery Today
|
July 20, 2019
The Art of Virtualizing Pharma R&D
Alexander Schuhmacher, Oliver Gassmann, Michael Kuss, et al.
Journal of Translational Medicine
|
May 10, 2018
Open innovation and external sources of innovation. An opportunity to fuel the R&D pipeline and enhance decision making?
Alexander Schuhmacher, Oliver Gassmann, Nigel McCracken, et al.
Drug Discovery Today
|
August 3, 2024
Comparative analysis of FDA approvals by top 20 pharma companies (2014-2023)
Alexander Schuhmacher, Oliver Gassmann, Markus Hinder, et al.
Drug Discovery Today
|
September 20, 2025
The Role of Data Monitoring Committees in drug research
Markus Hinder, Nandhini Madesh, Dominik Hartl, et al.
Clinical Pharmacology and Therapeutics
|
January 10, 2018
Developing Drugs for Heart Failure With Reduced Ejection Fraction: What Have We Learned From Clinical Trials?
Markus Hinder, B Alexander Yi, Thomas H Langenickel
Drug Discovery Today
|
August 4, 2020
The present and future of project management in pharmaceutical R&D
Alexander Schuhmacher, Oliver Gassmann, Markus Hinder, et al.
Drug Discovery Today
|
June 1, 2022
Open innovation: A paradigm shift in pharma R&D?
Alexander Schuhmacher, Oliver Gassmann, Doria Bieniok, et al.
Page
of 5